Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06903338 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
A Phase 3 study of Viral Hepatitis, sponsored by Vir Biotechnology.
- Active
- Registry status
- Phase 3
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT06903338 is a Phase 3 study of Viral Hepatitis that is active but no longer recruiting, run by Vir Biotechnology. The registered enrollment target is 124 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT06903338, a Phase 3 study of Viral Hepatitis, is active but no longer recruiting, sponsored by Vir Biotechnology.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
Conditions Studied
Interventions
- DRUG Tobevibart
- DRUG Elebsiran
Study Locations (20)
Other
- Investigative Site - Montreal
- Investigative Site - Ottawa
- Investigative Site - Québec
- Investigative Site - Vancouver
- Investigative Site - Tbilisi
California
- Investigative Site - Los Angeles
- Investigative Site - Redwood City
- Investigative Site - San Francisco
New York
- Investigative Site - New York
- Investigative Site - New York
- Investigative Site - New York
Arizona
- Investigative Site - Chandler
Florida
- Investigative Site - DeLand
Illinois
- Investigative Site - Chicago
Maryland
- Investigative Site - Baltimore
New Jersey
- Investigative Site - Hillsborough
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2031-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06903338
The ClinicalTrials.gov registry entry for NCT06903338 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vir Biotechnology, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Viral Hepatitis appearing as the primary indexed condition, and to 2 interventions - of which Tobevibart is the first listed.
NCT06903338 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT06903338 about?
NCT06903338 is a clinical study titled "A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection". This is a multicenter, open label, randomized Phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.
What is the current status of trial NCT06903338?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 124 participants. The study started on 2025-03-12. Estimated completion is 2031-05.
What conditions does trial NCT06903338 study?
This clinical trial studies the following conditions: Viral Hepatitis.
What interventions are being tested in trial NCT06903338?
The interventions under investigation include: Tobevibart (DRUG), Elebsiran (DRUG).
Who is sponsoring clinical trial NCT06903338?
This trial is sponsored by Vir Biotechnology, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06903338 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Hepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.